Ep182: Andy Rachleff & Yung Lie on Creative Ways to Back Science

Episode Summary

Executive Summary: The episode examines how U.S. science—especially basic biomedical research—is being strained by federal cuts, uncertainty, and anti-science rhetoric, and how Damon Runyon is responding by extending support for young investigators and launching a seed-investment program for alumni founders. Jung Lee and Andy Ratcliffe argue that high-risk, high-reward funding of young scientists remains the best path to breakthroughs and that philanthropy must be catalytic, not substitutive, amid broader attacks on the research ecosystem.

Main Topics: Federal attacks on science and research stability (Priority: 5/5): The conversation opens with a detailed account of NIH staff cuts, grant cancellations, disrupted review processes, and proposed reductions in indirect costs, framing 2025 as a destabilizing year for biomedical research and universities. Damon Runyon’s mission to fund young scientists (Priority: 5/5): Lee explains that Damon Runyon supports early-career cancer researchers with funding and community at key career moments, emphasizing freedom to pursue bold ideas and follow unexpected results. Venture capital logic applied to philanthropy (Priority: 5/5): Ratcliffe argues that scientific funding should prioritize upside over batting average, using VC-style power-law thinking to back a small number of highly impactful bets rather than consensus projects. Bridge funding and retention during uncertainty (Priority: 4/5): Damon Runyon is using endowment resources to provide one-year extensions for vulnerable young scientists whose career transitions are threatened by hiring freezes, lost federal funding, and visa insecurity. The Invest seed-capital program (Priority: 5/5): The foundation is launching a program that writes $50,000 checks to alumni scientists who have already raised $500,000, aiming to catalyze startup formation and recycle future returns into grants. Brain drain, immigration, and global competition (Priority: 4/5): Lee warns that visa and immigration pressures are making international trainees feel unwelcome and increasing the risk that talent will move to other countries offering stronger support. Science communication and public trust (Priority: 4/5): The episode closes with a call for scientists to communicate better with the public, reduce the gap between research and society, and counter misleading narratives about NIH overhead and waste.

Key Arguments: High-risk, high-reward research is where major breakthroughs come from, especially when funding young scientists with bold ideas. Scientific funding should be evaluated by slugging percentage, not batting average: a few successes can justify many failed bets. Damon Runyon’s model is unusually impactful because it funds early-career investigators across cancer types rather than narrow disease silos. Nonprofits cannot replace federal science funding, but they can strategically extend careers, preserve talent, and catalyze external investment. The new Invest program leverages Damon Runyon’s alumni network as its strongest asset, using small seed checks to unlock much larger venture rounds. Federal uncertainty and immigration pressures are threatening the pipeline of future scientists and could accelerate a brain drain to other countries. Scientists need more freedom, breathing room, and support to follow serendipitous findings that often lead to breakthrough discoveries. Public misunderstanding of NIH overhead and research administration has been used to justify cuts, when much of the cost reflects infrastructure and compliance rather than waste.

Data Points: Damon Runyon annual budget: about $20 million - Size of the foundation relative to the federal science budget Proposed NIH indirect cost rate cap: 15% - Department of Government Efficiency proposal that would cut university research support NIH staff jobs cut: about 1,200 - Described as part of the 2025 disruption to biomedical research NIH grants canceled: more than 2,500 - With about 900 later reinstated NIH grants reinstated: about 900 - Partial reversal of earlier cancellations Federal basic research spending at risk: about one-third - AAAS analysis of the FY2026 White House budget proposal Damon Runyon alumni since 1946: over 4,000 - Foundation’s long-term scientific network Damon Runyon alumni Nobel laureates: 13 - Evidence of the program’s outsized impact Damon Runyon alumni in National Academy of Sciences: about 100 - Another indicator of scientific influence Invest program check size: $50,000 - Seed investment per alumni scientist/company Minimum external fundraising required for Invest: $500,000 - Threshold to qualify for Damon Runyon seed check Expected annual Invest deals: 10 to 20 - Projected number of seed investments each year Invest annual capital deployment: $500,000 to $1 million - Calculated from expected number of $50,000 checks Endowment size: about $150 million - Base from which the foundation can allocate up to 5% for Invest Potential Stanford early investment value: more than $400 million - Ratcliffe’s example of the long-run payoff from small, patient investments Average age of first-time NIH grant winner: around 40 to 41 - Used to argue that the system favors older investigators Average age at Nobel-winning discovery: 36 - Supports the case for funding young scientists earlier Share of scientists funded who are non-U.S.: over 50% - Highlights immigration and visa vulnerability Share of NIH budget for high-risk, high-reward innovation (historic example): $5 million out of $30 billion - Historical reference to the NIH Director’s Pioneer Award Current high-risk, high-reward share of NIH budget: less than 1% - Lee’s estimate of present allocation Approximate number of potential seed investments Stanford model initially made: 10 per year - Derived from 5 firms x 2 investments each under the model

Pivotal Quotes: "The key to success in venture capital is not the percentage of the time that you're correct, but the magnitude of the success when you are." — Andy Ratcliffe: Explaining why Damon Runyon should prioritize a few breakthrough bets over consensus funding "Breakthroughs come from, you know, being able to give our scientists the freedom to, as Andy and his colleagues say, savor the surprises and embrace serendipity when it comes." — Jung Lee: Describing why Damon Runyon gives scientists room to follow unexpected findings "Science is under attack." — Andy Ratcliffe: Summarizing the broader threat he sees to universities and the biomedical research system

Implications: If federal support remains unstable, philanthropy must become more strategic: bridge talent, back young scientists, and fund translation. The episode argues that science’s future depends on protecting people, not just projects.